Regulatory, legislative, and policy updates with anticoagulant use

详细信息    查看全文

• 作者：John Fanikos (1)
  Leo F. Buckley (1)
  Ahmed Aldemerdash (1)
  Kimberly J. Terry (1)
  Gregory Piazza (2)
  Jean M. Connors (3)
  Samuel Z. Goldhaber (2)
  
  1. Department of Pharmacy Services ; Brigham and Women鈥檚 Hospital ; 75 Francis Street ; Boston ; MA ; 02115 ; USA
  2. Divisions of Cardiovascular Medicine ; Department of Medicine ; Brigham and Women鈥檚 Hospital ; Harvard Medical School ; Boston ; MA ; USA
  3. Divisions of Hematology ; Department of Medicine ; Brigham and Women鈥檚 Hospital ; Harvard Medical School ; Boston ; MA ; USA
  
• 关键词：Venous thromboembolism ; Stroke ; Anticoagulation ; Regulatory affairs ; Health policy
• 刊名：Journal of Thrombosis and Thrombolysis
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：39
• 期：3
• 页码：273-287
• 全文大小：2,015 KB
• 参考文献：1. Roger, VL, Go, AS, Lloyd-Jones, DM (2012) Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125: pp. e2-e220 CrossRef
  2. Brown, DL, Boden-Albala, B, Langa, KM (2006) Projected costs of ischemic stroke in the United States. Neurology 67: pp. 1390-1395 CrossRef
  3. Mahan, CE, Borrego, ME, Woersching, AL (2012) Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost 108: pp. 291-302 CrossRef
  4. Huang, W, Goldberg, RJ, Anderson, FA (2014) Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985鈥?009). Am J Med 127: pp. 829-839 CrossRef
  5. Fanikos, J, Stapinski, C, Koo, S (2014) Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol 94: pp. 532-535 5" target="_blank" title="It opens in new window">CrossRef
  6. Piazza, G, Nguyen, TN, Cios, D (2011) Anticoagulation-associated adverse drug events. Am J Med 124: pp. 1136-1142 CrossRef
  7. US Department of Health and Human Services, Office of Disease Prevention and Health Promotion (2014) National action plan for adverse drug event prevention. Washington, DC
  8. Mahan, CE (2012) Regulatory, policy and quality update for venous thromboembolism and stroke in United States hospitals. Thromb Res 130: pp. 586-590 CrossRef
  9. Dusetzina, SB, Higashi, AS, Dorsey, ER (2012) Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care 50: pp. 466-478 5a160" target="_blank" title="It opens in new window">CrossRef
  10. Chassin, MR, Loeb, JM, Schmaltz, SP (2010) Accountability measures鈥攗sing measurements to promote quality improvement. N Engl J Med 363: pp. 683-688 56/NEJMsb1002320" target="_blank" title="It opens in new window">CrossRef
  11. The Joint Commission (2014) Facts about ORYX^庐 for hospitals (National Hospital Quality Measures). http://www.jointcommission.org/facts_about_oryx_for_hospitals. Accessed 5 Feb 2015
  12. The Joint Commission (2014) 2015 flexible ORYX performance measure reporting options. 5_OPTIONS_UPDATED_11-4_15.pdf" class="a-plus-plus">http://www.jointcommission.org/assets/1/18/2015_OPTIONS_UPDATED_11-4_15.pdf. Accessed 5 Feb 2015
  13. Consumer Purchaser Alliance (2014) FACT SHEET: Hospital Inpatient Quality Reporting (IQR) Program. http://consumerpurchaser.org/files/IQR_FactSheet.pdf. Accessed 5 Feb 2015
  14. The Centers for Medicare and Medicaid Services (2014) Fact sheets: CMS to improve quality of care during hospital inpatients stays. http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2014-Fact-sheets-items/2014-08-04-2.html. Accessed 5 Feb 2015
  15. The Centers for Medicare and Medicaid Services (2014) Fact sheets: Fiscal Year 2015 policy and payment changes for inpatient stays in acute-care hospitals and long-term care hospitals. http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2014-Fact-sheets-items/2014-08-04.html. Accessed 5 Feb 2015
  16. The National Quality Forum (2010) National voluntary consensus standards for stroke prevention and management across the continuum of care: a consensus report. of_Care.aspx" class="a-plus-plus">http://www.qualityforum.org/Publications/2010/02/National_Voluntary_Consensus_Standards_for_Stroke_Prevention_and_Management_Across_the_Continuum_of_Care.aspx. Accessed 2 Dec 2014
  17. LaBresh, KA, Reeves, MJ, Frankel, MR (2008) Hospital treatment of patients with ischemic stroke or transient ischemic attack using the 鈥淕et With The Guidelines鈥?program. Arch Intern Med 168: pp. 411-417 CrossRef
  18. Fonarow, GC, Reeves, MJ, Smith, EE (2010) Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in 鈥淕et with the Guidelines鈥?stroke. Circ Cardiovasc Qual Outcomes 3: pp. 291-302 58" target="_blank" title="It opens in new window">CrossRef
  19. Johnson, AM, Goldstein, LB, Bennett, P (2014) Compliance with acute stroke care quality measures in hospitals with and without primary stroke center certification: the North Carolina Stroke Care Collaborative. J Am Heart Assoc 3: pp. e000423 CrossRef
  20. Parker, C, Schwamm, LH, Fonarow, GC (2012) Stroke quality metrics: systematic reviews of the relationships to patient-centered outcomes and impact of public reporting. Stroke 43: pp. 155-162 5011" target="_blank" title="It opens in new window">CrossRef
  21. Blatzer, D, Hunt, D (2006) The Surgical Infection Prevention and Surgical Care Improvement Projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis 43: pp. 322-330 505220" target="_blank" title="It opens in new window">CrossRef
  22. Stratton, MA, Anderson, FA, Bussey, HI (2000) Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med 160: pp. 334-340 CrossRef
  23. Altom, LK, Deierhoi, RJ, Grams, J (2012) Association between Surgical Care Improvement Program venous thromboembolism measures and postoperative events. Am J Surg 204: pp. 591-597 CrossRef
  24. Hawn, MT, Itani, KM, Gray, SH (2008) Association of timely administration of prophylactic antibiotics for major surgical procedures and surgical site infection. J Am Coll Surg 206: pp. 814-819 CrossRef
  25. Januel, J-M, Chen, G, Ruffieux, C, Quan, H, Douketis, JD, Crowther, MA (2012) Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. JAMA 307: pp. 294-303 CrossRef
  26. Heit, JA (2012) Estimating the incidence of symptomatic postoperative venous thromboembolism: the importance of perspective. JAMA 307: pp. 306-307 CrossRef
  27. Bilimoria, KY, Chung, J, Ju, MH (2013) Evaluation of surveillance bias and the validity of the venous thromboembolism quality measure. JAMA 310: pp. 1482-1489 CrossRef
  28. White, RH, Sadeghi, B, Tancredi, DJ (2009) How valid is the ICD-9-CM based AHRQ patient safety indicator for postoperative venous thromboembolism?. Med Care 47: pp. 1237-1243 58940" target="_blank" title="It opens in new window">CrossRef
  29. US Department of Health and Human Services, Centers for Medicare and Medicaid Services (2014) CMS to improve quality of care during hospital inpatient stays [Internet]. http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2014-Fact-sheets-items/2014-08-04-2.html. Accessed 4 Dec 2014
  30. Centers for Medicare and Medicaid Services. Hospital-acquired conditions (present on admission indicator). http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/Downloads/FY_2013_Final_HACsCodeList.pdf. Accessed 2 Dec 2014
  31. US Department of Health and Human Services (2014) Interim update on 2013 annual hospital-acquired condition rate and estimates of cost savings and deaths averted from 2010 to 2013. ofessionals/quality-patient-safety/pfp/interimhacrate2013.pdf" class="a-plus-plus">http://www.ahrq.gov/professionals/quality-patient-safety/pfp/interimhacrate2013.pdf. Accessed 2 Dec 2014
  32. The Centers for Medicare and Medicaid Services (2014) 2014 definition of Stage 1 of Meaningful Use. http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Meaningful_Use.html. Accessed 5 Feb 2015
  33. Holbrook, A, Schulman, S, Witt, DM (2012) Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2: pp. e152S-e184S
  34. The Joint Commission (2014) 2014 Hospital National Patient Safety Goals. [Internet]. http://jointcomission.org/assets/1/6/2014_HAFP_NPSG_E.pdf. Accessed 4 Dec 2014
  35. Institute for Safe Medication Practices (2002) Organizations release new tools for reducing medication errors. http://ismp.org/tools/pathways.asp. Accessed 4 Dec 2014
  36. The National Quality Forum (2013) Measures, reports & tools. http://www.qualityforum.org/measures_reports_tools.aspx. Accessed 4 Dec 2014
  37. Nutescu, EA, Wittkowsky, AK, Burnett, A (2013) Delivery of optimized inpatient anticoagulation therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother 47: pp. 714-724 5/aph.1R634" target="_blank" title="It opens in new window">CrossRef
  38. Rudd, KM, Dier, JG (2010) Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy 30: pp. 330-338 592/phco.30.4.330" target="_blank" title="It opens in new window">CrossRef
  39. Witt, DM, Humphries, TL (2003) A retrospective evaluation of the management of excessive anticoagulation in an established clinical pharmacy anticoagulation service compared to traditional care. J Thromb Thrombolysis 15: pp. 113-118 5.62542.43" target="_blank" title="It opens in new window">CrossRef
  40. Bungard, TJ, Gardner, L, Archer, SL (2009) Evaluation of a pharmacist-managed anticoagulation clinic: improving patient care. Open Med 3: pp. e16-e21
  41. Ansell, JE, Hughes, R (1996) Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 132: pp. 1095-1100 CrossRef
  42. Gray, DR, Garabedian-Ruffalo, SM, Chretien, SD (2007) Cost-justification of a clinical pharmacist-managed anticoagulation clinic. Ann Pharmacother 41: pp. 496-501 5/aph.140056" target="_blank" title="It opens in new window">CrossRef
  43. Behrman, RE, Benner, JS, Brown, JS (2011) Developing the Sentinel System鈥攁 national resource for evidence development. N Engl J Med 364: pp. 498-499 56/NEJMp1014427" target="_blank" title="It opens in new window">CrossRef
  44. Psaty, BM, Breckenridge, AM (2014) Mini-Sentinel and regulatory science鈥攂ig data rendered fit and functional. N Engl J Med 370: pp. 2165-2167 56/NEJMp1401664" target="_blank" title="It opens in new window">CrossRef
  45. Institute for Safe Medication Practices (2010) Monitoring MedWatch Reports: signals for two newly approved drugs and 2010 Annual Summary. QuarterWatch
  46. Institute for Safe Medication Practices (2012) Signals for dabigatran and metoclopramide. QuarterWatch
  47. Mini-Sentinel (2013) Health outcomes among individuals exposed to medical product details: dabigatran, warfarin & GI bleed, intracerebral hemorrhage [Internet]. http://www.mini-sentinel.org/work_products/Assessments/Mini-Sentinel_Modular-Program-Report_MSY3_MPR41_Dabigatran-Warfarin-GIH-ICH_Part-1.pdf. Accessed 2 Dec 2014
  48. Mini-Sentinel (2013) Health outcomes among individuals exposed to medical product details: dabigatran, warfarin & GI bleed, intracerebral hemorrhage. http://www.mini-sentinel.org/work_products/Assessments/Mini-Sentinel_Modular-Program-Report_MSY3_MPR41_Dabigatran-Warfarin-GIH-ICH_Part-2.pdf. Accessed 2 Dec 2014
  49. Mini-Sentinel (2013) Prospective Routine Observational Monitoring Program Tools (PROMPT): Rivaroxaban Surveillance Plan v2.0 [Internet]. http://www.mini-sentinel.org/work_products/Assessments/Mini-Sentinel_PROMPT_Rivaroxaban-Surveillance-Plan.pdf. Accessed 1 Dec 2014
  50. Rosaia, L (2010) Heparin crisis 2008: a tipping point for increased FDA enforcement in the pharma sector?. Food Drug Law J 65: pp. 489-501
  51. Barlas, S (2014) FDA starts new light-touch inspections for some imports. P&T. 39: pp. 384-385
  52. US Department of Health and Human Services, Food and Drug Administration (2014) Food and Drug Administration Safety and Innovation Act. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/. Accessed 4 Dec 2014
  53. US Department of Health and Human Services, Food and Drug Administration (2014) Drug Supply Chain Security Act. http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/. Accessed 4 Dec 2014
  54. United States Judicial Panel on Multistate Legislation. Pradaxa (dabigatran etexilate) products liability litigation. MDL 2385, Document 106
  55. United States Judicial Panel on Multistate Legislation. Xarelto (rivaroxaban) products liability litigation MDL 2592, Document 122
  56. Thomas K (2014) Study of drug for blood clots caused a stir, records show. New York Times
  57. Cohen, D (2014) Dabigatran: how the drug company withheld important analyses. Br Med J 349: pp. g4670 CrossRef
  58. Kmietowicz, Z (2014) Boehringer Ingelheim withheld safety analyses on new anticoagulant, The BMJ investigation finds. Br Med J 349: pp. g4756 56" target="_blank" title="It opens in new window">CrossRef
  59. Reilly, PA, Lehr, T, Haertter, S (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63: pp. 321-328 CrossRef
  60. European Medicines Agency (2008) European public assessment report (EPAR) for Pradaxa [internet]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp. Accessed 1 Dec 2014
  61. European Medicines Agency (2012) Minutes and answers from the CHMP ad hoc advisory group for PRADAXA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  Hematology
  
• 出版者：Springer Netherlands
• ISSN：1573-742X

文摘

Thromboembolism afflicts millions of patients annually in the United States and is associated with a significant cost burden. Recent advances in oral anticoagulation have provided clinicians with more options for management of these diseases. Accordingly, regulatory, legislative, and policy-making organizations have intervened with the aim of improving patient outcomes, ensuring patient safety, and reducing costs. There have been a number of recent developments in surveillance, litigation, and regulatory oversight that clinicians should recognize. In this review article we summarize key updates related to the management of anticoagulant therapy as it relates to thrombosis prevention and treatment.